Cagrilintide and semaglutide together drive record weight loss in global trial Once weekly cagrilintide for weight management in people with overweight and obesity: a multicentre, randomised, double blind, placebo controlled and active controlled, dose finding phase 2 trial The Lancet Cagrilintide powder for obesity and type 2 diabetes Lyra Zhao posted on the topic LinkedIn Semaglutide, a glucagon like peptide 1 (GLP 1) receptor agonist, has well established weight loss benefits. Cagrilintide, a long acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential benefit Semaglutide Cagrilintide Blend Biogynx Cagrilintide Semaglutide Blend 5mg 5mg Heritage Labs USA